骨髓瘤硼替佐米耐药相关突变分解.pptxVIP

  • 28
  • 0
  • 约 8页
  • 2016-12-18 发布于湖北
  • 举报
MM硼替佐米相关突变2015-11-16NRAS、KRASPSMB5NF-κB通路持续活化相关HSP:HSP90HSP27方法:MassARRAY®DNA质谱阵列基因分析NRAS-MUT:1、硼替佐米单药耐药相关2、PFS时间短3、不影响硼替佐米联合大剂量DEX方案化疗的患者的预后Interestingly,KRASbutnotNRASmutationwassignificantlyassociatedwithTP53mutation(15%ofthosewithKRASmutationversus3%ofthosewithout,P=0.014). whenweanalyzedtheimpactofKRASandNRASmutationsonsurvivalseparately,onlyKRASandnotNRASmutationsweresignificantlyassociatedwithshorteroverallsurvivalandprogressionfreesurvival. 体外实验:weheredevelopedhighlevels(45-to129-fold)ofacquiredresistancetobortezomibinhumanmyelomonocyticTHP1cellsbyexposuretostepwiseincreasing(2.5-200nM

文档评论(0)

1亿VIP精品文档

相关文档